Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00703313 · ClinicalTrials.gov registry record · Phase 4
Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators
A Phase 4 study, sponsored by Santen.
- Completed
- Registry status
- Phase 4
- Development phase
- 72
- Enrollment target
NCT00703313 is a Phase 4 study that has completed, run by Santen. The registered enrollment target is 72 participants.
The verdict
NCT00703313, a Phase 4 study, has completed, sponsored by Santen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 72 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the concentration in human tears of levofloxacin and the active comparators at 15 minutes, 2,6, 12, and 24 hours after instillation of a single drop of medication.
Interventions
- DRUG 1.5% levofloxacin ophthalmic solution
- DRUG 0.5% moxifloxacin hydrochloride ophthalmic solution
- DRUG 0.3% gatifloxacin ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2008-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00703313
The ClinicalTrials.gov registry entry for NCT00703313 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Santen, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 1.5% levofloxacin ophthalmic solution is the first listed.
NCT00703313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00703313 about?
NCT00703313 is a clinical study titled "Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators". The primary objective of this study is to compare the concentration in human tears of levofloxacin and the active comparators at 15 minutes, 2,6, 12, and 24 hours after instillation of a single drop of medication.
What is the current status of trial NCT00703313?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 72 participants. The study started on 2008-05.
What interventions are being tested in trial NCT00703313?
The interventions under investigation include: 1.5% levofloxacin ophthalmic solution (DRUG), 0.5% moxifloxacin hydrochloride ophthalmic solution (DRUG), 0.3% gatifloxacin ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT00703313?
This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.